Early onset type 2 diabetes is a growing global health problem in adolescents and young adults, especially in countries with a low-middle and middle sociodemographic index. A greater disease burden in women aged <30 years was found (BMJ)
Diabetes News
Tag: Type 2 Diabetes
Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels
In this comparative effectiveness and safety research study among adults with T2D, SGLT2i vs DPP-4i treatment initiators had a reduced risk of modified MACE and HHF, an increased risk of genital infections and DKA, and a lower risk of AKI, regardless of baseline HbA1 (JAMA)
Clinical expert consensus on the assessment and protection of pancreatic islet β-cell function in type 2 diabetes mellitus
Some measures, including weight loss and early and sustained euglycemia control, could effectively protect islet β-cell function, and some newly developed drugs, such as Sodium-glucose cotransporter-2 inhibitor and Glucagon-like peptide-1 receptor agonists, could improve islet β-cell function, independent of glycemic control (Diabetes Research and Clinical Practice)
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes (The Lancet Diabetes & Endocrinology)
Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes
Our results showed that more patients with iDegLira had HbA1c less than 7% and these combination had better effect on weight loss. There was no difference observed in FPG and PPG, lipid profile and rate of hypoglycaemia (BMC Endocrine Disorders)
Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA, and CARMELINA: assessment of a novel staging system for type 2 diabetes
Applying the DSS across T2D clinical trial populations with different CV risk revealed significantly increased risk for ACM and CV death with higher DSS stage. The DSS may benefit from assessment in other T2D populations and with evaluation of the impact of additional outcomes, such as heart failure (Diabetes, Obesity and Metabolism)
Meta-Analysis of Head-to-Head Clinical trials Comparing Incretin-Based Glucose-Lowering Medications and Basal Insulin – An Update Including Recently Developed GLP-1 Receptor Agonists and the GIP/GLP-1 Receptor Co-Agonist Tirzepatide
In particular, recently introduced, highly effective IBGLM were superior over basal insulin treatment, reinforcing the recommendation that IBGLM should be considered as the first injectable treatment for most patients with type 2 diabetes (Diabetes, Obesity and Metabolism)
Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial
Glycaemic control and hypoglycaemia worry improved significantly up to 24 months after switching from isCGM without alerts to rtCGM with alerts, supporting the use of rtCGM in the care of adults with type 1 diabetes (The Lancet Diabetes & Endocrinology)
Bariatric-metabolic surgery for NHS patients with type 2 diabetes in the United Kingdom National Bariatric Surgery Registry
NHS bariatric-metabolic surgery is used for people with T2DM much later in the disease process when it is less effective. National guidance on bariatric-metabolic surgery and data from multiple RCTs have had little impact on clinical practice (Diabetic Medicine)
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease
Dapagliflozin reduced the risk for hospitalization for any cause in patients with CKD with and without type 2 diabetes (Annals of Internal Medicine)
A Microbiome-targeting Fiber-enriched Nutritional Formula is Well Tolerated and Improves Quality of Life and Hemoglobin A1c in Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Trial
A microbiome-targeting nutritional formula significantly improved cT2-DDAS and HbA1c, suggesting the potential for prebiotic fiber as a complement to lifestyle and/or pharmaceutical interventions for managing type 2 diabetes (Diabetes, Obesity and Metabolism)
Are social determinants of health associated with the development of early complications among young adults with type 2 diabetes? A population based study using linked databases
In this multi-ethnic population, non-Western origin was associated with the development of complications, but only in men. Low income was not associated with developing complications. The importance of adequate HbA1c regulation was re-emphasized by this study (Primary Care Diabetes)
Bariatric-metabolic surgery for NHS patients with type 2 diabetes in the United Kingdom National Bariatric Surgery Registry
NHS bariatric-metabolic surgery is used for patients with T2DM much later in the disease process when it is less effective. National guidance on bariatric-metabolic surgery and data from multiple RCTs have had little impact on clinical practice (Diabetic Medicine)
Progress in genetics of type 2 diabetes and diabetic complications
Using multi-omics analysis, comprehensive molecular mechanisms have been elucidated to guide the development of targeted therapy for type 2 diabetes and diabetic complications (Journal of Diabetes Investigation)
Cardiovascular outcomes in type 1 and type 2 diabetes
As illustrated by the literature discussed above, comparison between individuals with type 1 and type 2 diabetes with respect to risk of CVD is fraught with difficulties and highly dependent on other concomitant factors, some of which are modifiable and others not (Diabetologia)
Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study
The STREAM study revealed that sitagliptin treatment effectively improved the glycemic profile without any serious adverse effects, including self-reported hypoglycemia, in older T2D patients (Nature Briefing)
High-density lipoprotein subclasses and cardiovascular disease and mortality in type 2 diabetes: analysis from the Hong Kong Diabetes Biobank
Small HDL-P were inversely associated with incident CVD and all-cause mortality and improved risk stratification for adverse outcomes in people with T2D. HDL-P may be used as markers for residual risk in people with T2D (Cardiovascular Diabetology)
Does the design of the NHS Low Calorie Diet Programme have fidelity to the programme specification?
A documentary review of service parameters and behaviour change content in a Type 2 Diabetes intervention (Diabetic Medicine)
Observational Evaluations of Disease Management Programs for Diabetes: The Proof Is in the Concept
Despite the introduction of multiple novel therapeutics over the past two decades, rates of control in type 2 diabetes (T2D) and its comorbidities remain suboptimal and may have even declined (Diabetic Care)
‘No one ever asks about something that actually is relevant to my life’
A qualitative study of diabetes and diabetes care experiences of young women with type 2 diabetes during their reproductive years (Diabetic Medicine)
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 68
- Next Page »
Glycosmedia is also available as an App: